Name: Do topical JAK inhibitors and oral JAK inhibitors have similar rates of systemic adverse events?
Uploaded: 2021-10-14T00:00:00.000Z
Description: Do topical JAK inhibitors and oral JAK inhibitors have similar rates of systemic adverse events?

Welcome to Dermbits! Watch short videos of KOLs answering your questions

thumbnail_dermbits-colorful.png

dermbits-colorful.png

Dermbits

Do topical JAK inhibitors and oral JAK inhibitors have similar rates of systemic adverse events?

Atopic Dermatitis

You. Topical jack inhibitors have much, much less concerns about systemic side effects because the systemic absorption is so much less. With regard to ruxolithidib, 50 milligram oral ruxolithinib was compared directly against 1.5% topical agent used up to 90% of the body surface. And what happened was that the plasma blood level less than 100 nanometer nanomols for the topical, which is about one six of what happened with the oral. And this is so much less than the blood level necessary to affect the blood count. So topical is so much more safer than oral in terms of systemic side effects.

Do topical JAK inhibitors and oral JAK inhibitors have similar rates of systemic adverse events?

Related CME